Anti-endotoxin therapeutic options for the treatment of sepsis

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. A, 1998, Pages 71-80

  Lynn, William A ^a  

^a EALING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CD14 ANTIGEN; ENDOTOXIN; ENDOTOXIN ANTIBODY; LIPID A; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; PROTEIN;

BACTERIAL CELL WALL; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CLINICAL RESEARCH; COMPETITIVE INHIBITION; CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MORBIDITY; MORTALITY; NEUTROPHIL; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031965409     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_1.71     Document Type: Conference Paper

References (78)

1. Raetz, C. R. H., Ulevitch, R. J. Wright, S. D., Sibley, C. H., Ding, A. & Nathan, C. F. (1991). Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB Journal 5, 2652-60.
2. Tobias, P. S., Mathison, J., Mintz, D., Lee, J. D., Kravchenko, V., Kato, K. et al. (1992). Participation of lipopolysaccharidebinding protein in lipopolysaccharide-dependent macrophage activation. American Journal of Respiratory Cell and Molecular Biology 7, 239-45.
3. Lynn, W. A. & Cohen, J. (1995). Adjunctive therapy for septic shock: a review of experimental approaches. Clinical Infectious Diseases 20, 143-58.
4. Rietschel, E. T. & Brade, H. (1992). Bacterial endotoxins. Scientific American 267, 54-61.
5. Braude, A. I. & Douglas, H. (1972). Passive immunization against the local Shwartzman reaction. Journal of Immunology 108, 505-12.
6. McCabe, W. R. & Greely, A. (1972). Immunization with R mutants of S. minnesota. 1. Protection against challenge with heterologous Gram-negative bacilli. Journal of Immunology 108, 601-10.
7. Taveira daSilva, A. M., Kaulbach, H. C., Chuidian, F. S., Lambert, D. R., Suffredini, A. F. & Danner, R. L. (1993). Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. New England Journal Of Medicine 328, 1457-60.
8. Freudenberg, M. A., Freudenberg, N. & Galanos, C. (1982). Time course and cellular distribution of endotoxin in liver, lungs and kidneys of rats. British Journal of Experimental Pathology 63, 56-65.
9. Schumann, R. R., Leong, S. R., Flaggs, G. W., Gray, P. W., Wright, S. D., Mathison, J. C. et al. (1990). Structure and function of lipopolysaccharide binding protein. Science 249, 1429-31.
10. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J. & Mathison, J. C. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-3.
11. Ziegler-Heitbrock, H. W. L. & Ulevitch, R. J. (1993). CD14: cell surface receptor and differentiation marker. Immunology Today 14, 121-5.
12. Lynn, W. A., Liu, Y. & Golenbock, D. T. (1993). Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infection and Immunity 61, 4452-61.
13. Ingalls, R. R. & Golenbock, D. T. (1995). CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. Journal of Experimental Medicine 181, 1473-9.
14. Hampton, R. Y., Golenbock, D. T., Penman, M., Krieger, M. & Raetz, C. R. H. (1991). Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 352, 342-4.
15. Pugin, J., Ulevitch, R. J. & Tobias, P. S. (1995). Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD 14. Progress in Clinical and Biological Research 392, 369-73.
16. Frey, E. A., Miller, D. S., Jahr, T. G., Sundan, A., Bazil, V, Espevik, T. et al. (1992). Soluble CD14 participates in the response of cells to lipopolysaccharide. Journal of Experimental Medicine 176, 1665-71.
17. Landmann, R., Zimmerli, W., Sansano, S., Link, S., Hahn, A., Glauser, M. P. et al. (1995). Increased circulating CD14 is associated with high mortality in Gram-negative septic shock. Journal of Infectious Diseases 171, 639-44.
18. Flegel, W. A., Baumstark, M. W., Weinstock, C., Berg, A. & Nortoff, H. (1993). Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-1. Infection and Immunity 61, 5140-6.
19. Elsbach, P. & Weiss, J. (1995). Prospects for use of recombined BPI in the treatment of Gram-negative bacterial infections. Infectious Agents and Disease 4, 102-9.
20. Munford, R. S. & Hall, C. L. (1986). Detoxification of bacteria lipopolysaccharides (endotoxins) by a human neutrophil enzyme. Science 234, 203-5.
21. Appelmelk, B. & Cohen, J. (1992). The protective role of antibodies to the lipopolysaccharide core region. In Bacterial Endotoxic Lipopolysaccharides (Ryan, J. L. & Morrison, D. C., Eds), pp. 375-413. CRC Press, Boca Raton, FL.
22. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H. et al. (1982). Treatment of Gramnegative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307, 1225-30.
23. The Intravenous lmmunoglobulin Collaborative Study Group. (1992). Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. New England Journal of Medicine 327, 234-40.
24. Greenman, R. L., Schein, R. M. H., Martin, M. A., Wenzel, R. P., Maclntyre, N. R., Emmanuel, G. et al. (1991). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. Journal of the American Medical Association 266, 1097-102.
25. Bone, R. C., Balk, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D. et al. (1995). A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Critical Care Medicine, 23, 994-1006.
26. Ziegler, E. J., Fisher, C. J., Sprung, C. L., Strube, R. C., Sadoff, J. C., Foulke, G. E. et al. (1991). Treatment of Gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine 324, 429-36.
27. Teng, N. N. H., Kaplan, H. S., Herbert, J. M., Moore, C., Douglas, H., Wunderlich, A. et al. (1985). Protection against Gramnegative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Siences of the United States of America 82, 1790-4.
28. Krieger, J. I., Fletcher, R. C., Siegel, S. A., Fearon, D. T., Neblock, D. S., Boutin, R. H. et al. (1993). Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. Journal of Infectious Diseases 167, 865-75.
29. Warren, H. S., Danner, R. L. & Munford, R. S. (1992). Antiendotoxin monoclonal antibodies. New England Journal of Medicine 326, 1153-6.
30. McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M. & Smith, C. R. (1994). Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebocontrolled trial. CHESS Trial Study Group. Annals of Internal Medicine 121, 1-5.
31. Panacek, E. A., MacArthur, R. D. & Johnson, S. B. (1995). Results of a phase III clinical trial of the human monoclonal antibody MAb-TSS versus placebo in Gram-negative sepsis. In Society of Critical Care, San Francisco, 1995. Abstract 293.
32. Di Padova, F. E., Brade, H., Barclay, G. R., Poxton, I. R., Liehl, E., Schuetze, E. et al. (1993). A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infection and Immunity 61, 3863-72.
33. Opal, S. M., Cross, A. S., Sadoff, J. C., Collins, H. H., Kelly, N. M., Victor, G. H. et al. (1991). Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudonomas sepsis. Journal of Clinical Investigation 88, 885-90.
34. Saravolatz, L., Markowitz, N., Collins, M. S., Bogdanoff, D. & Pennington, J. E. (1991). Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeroginosa monoclonal antibodies in septic and non-septic patients. Journal of Infectious Diseases 164, 803-6.
35. Bhattacharjee, A. K., Opal, S. M., Taylor, R., Naso, R., Semenuk, M., Zollinger, W. D. et al. (1996). A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. Journal of Infectious Diseases 173, 1157-63.
36. Lynn, W. A., Raetz, C. R. H., Qureshi, N. & Golenbock, D. T. (1991). Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists. Journal of Immunology 147, 3072-9.
37. Haziot, A., Rong, G. W., Lin, X.-Y., Silver, J. & Goyert, S. M. (1995). Recombinant soluble CD14 presents mortality in mice treated with endotoxin (lipopolysaccharide). Journal of Immunology 154, 6529-32.
38. Gallay, P., Heumann, D., LeRoy, D., Barras, C. & Glauser, M. P. (1994). Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proceedings of the National Academy of Sciences of the United States of America 91, 7922-6.
39. 2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibits tumor necrosis factor release induced by the bacteria. Journal of Clinical Investigation 90, 1122-30.
40. Kohn, F. R., Ammons, W. S., Horwitz, A., Grinna, L., Theofan, G., Weickmann, J. et al. (1993). Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. Journal of Infectious Diseases 168, 1307-10.
41. 23. In Abstracts of the ThirtyFourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract M3, p. 65. American Society for Microbiology, Washington, DC.
42. Au-Young, J., Seilhamer, J. J., Lin, L., McKelligon, B. M., Lane, J. C., Snable, J. L. et al. (1995). A novel LBP-BPI fusion protein with in vivo efficacy and longer half-life. Journal of Endotoxin Research 2, 209-12.
43. Pereira, H. A. (1995). CAP37, a neutrophil-derived multifunctional inflammatory mediator. Journal of Leukocyte Biology 57, 805-12.
44. Hirata, M., Shimomura, Y., Yoshida, M., Wright, S. C. & Larrick, J.W. (1994). Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Progress in Clinical and Biological Research 388, 147-59.
45. Hirata, M., Shimomura, Y., Yoshida, M., Morgan, J. G., Palings, I., Wilson, D. et al. (1994). Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infection and Immunity 62, 1421-6.
46. Levy, O., Ooi, C. E., Elsbach, P., Doerfler, M. E., Lehrer, R. I. & Weiss, J. (1995). Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/ permeability-increasing protein, p15s, and defensins. Journal of Immunology 154, 5403-10.
47. Ooi, C. E., Weiss, J., Levy, O. & Elsbach, P. (1990). Isolation of two isoforms of a novel 15 kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. Journal of Biological Chemistry 265, 15956-62.
48. Alpert, G., Baldwin, G., Thompson, C., Wainwright, N., Novitsky, T. J., Gillis, Z. et al. (1992). Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. Journal of Infectious Diseases 165, 494-500.
49. Desch, C. E., O'Hara, P. & Harlan, J. M. (1989). Antilipopolysaccharide factor from horseshoe crab, Tachypleus tridentatus, inhibits lipopolysaccharide activation of cultured human endothelial cells. Infection and Immunity 57, 1612-4.
50. Saladino, R. A., Stack, A. M., Thompson, C., Sattler, F., Novitsky, T. J., Siber, G. R. et al. (1996). High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis. Critical Care Medicine 24, 1203-7.
51. Battafaraono, R. J., Dahlberg, P. S., Ratz, C. A., Johnston, J. W., Gray, B. H., Haseman, J. R. et al. (1995). Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery 118, 318-24.
52. Read, T. E., Grunfeld, C., Kumwenda, Z., Calhoun, M. C., Kane, J. P., Feingold, K. R. et al. (1995). Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery 117, 62-7.
53. van der Poll, T., Braxton, C. C., Coyle, S. M., Boermeester, M. A., Wang, J. C., Jansen, P. M. et al. (1995). Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infection and Immunity 63, 3396-400.
54. Morrison, D. C. & Jacobs, D. M. (1976). Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13, 813-8.
55. Danner, R. L., Joiner, K. A., Rubin, M., Patterson, W. H., Johnson, N., Ayers, K. M. et al. (1989). Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrobial Agents and Chemotherapy 33, 1428-34.
56. Bucklin, S. E., Lake, P., Lodgberg, L. & Morrison, D. C. (1995). Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrobial Agents and Chemotherapy 39, 1462-6.
57. Lynn, W. A. & Golenbock, D. T. (1992). Lipopolysaccharide antagonists. Immunology Today 13, 271-6.
58. Danner, R. L., Eichacker, P. Q., Doerfler, M. E., Hoffman, W. D., Reilly, J. M., Wilson, J. et al. (1993). Therapeutic trial of lipid X in a canine model of septic shock. Journal of Infectious Diseases 167, 378-84.
59. Golenbock, D. T., Hampton, R. Y., Qureshi, N., Takayama, K. & Raetz, C. R. H. (1991). Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. Journal of Biological Chemistry 266, 19490-8.
60. Loppnow, H., Brade, H., Durrbaum, I., Dinarello, C. A., Kusumoto, S., Rietschel, E. T. et al. (1989). IL-1 induction-capacity of defined lipopolysaccharide partial structures. Journal of Immunology 142, 3229-38.
61. Aida, Y., Kusumoto, K., Nakatomi, K., Takada, H., Pabst, M. J. & Maeda, K. (1995). An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. Journal of Leukocyte Biology 58, 675-82.
62. Kitchens, R. L., Ulevitch, R. J. & Munford, R. S. (1992). Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. Journal of Experimental Medicine 176, 485-94.
63. Delude, R. L, Savedra, R., Yamamoto, S. & Golenbock, D. T. (1995). Use of CD14 transfected cells to study LPS-antagonist action. Progress in Clinical and Biological Research 392, 487-97.
64. Christ, W. J., Ansano, O., Robidoux, A. L. C., Perez, M., Wang, Y., Dubuc, G. R. et al. (1995). E5531, a pure endotoxin antagonist of high potency. Science 268, 80-3.
65. Sato, K., Yoo, Y. C., Fukushima, A., Saiki, I., Takahashi, T. A., Fujihara, M. et al. (1995). A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia. Infection and Immunity 63, 2859-66.
66. Astiz, M. E., Rackow, E. C., Still. J. G., Howell, S. T., Cato, A., Von-Eschen, K. B. et al. (1995). Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: prospective, double-blind, randomized, controlled trial. Critical Care Medicine 23, 9-17.
67. Astiz, M. E., Saha, D. C., Brooks, K.,Carpati, C. M. & Rackow,E. C. (1993). Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide. Circulatory Shock 39, 194-8.
68. Bone, R. C. (1996). Sir Isaac Newton, sepsis, SIRS and CARS. Critical Care Medicine 24, 1125-7.
69. Astiz, M. E., Saha, D. C., Brooks, K., Carpati, C. M. & Rackow, E. C. (1993). Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide. Circulatory Shock 39, 194-8.
70. Rudbach, J. A., Myers, K. R., Rechtman, D. J. & Ulrich, J. T. (1994). Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis. Progress in Clinical and Biological Research 388, 107-24.
71. Reeves, J. H. & But, W. W. (1995). Blood filtration in children with severe sepsis: safe adjunctive therapy. Intensive Care Medicine 21, 500-4.
72. Cohen, J., Aslam, M., Pusey, C. D. & Ryan, C. J. (1987). Protection from endoloxemia: a rat model of plasmapheresis and specific adsorption by polymyxin B. Journal of Infectious Diseases 155, 690-5.
73. Aoki, H., Kodama, M., Tani, T. & Hanasawa, K. (1994). Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. American Journal of Surgery 167, 412-7.
74. Imaizumi, H., Yoshida, M., Satoh, M. & Shichinohe, Y. (1996). Effects of endotoxin removal by direct hemoperfusion using polymyxin B immobilized fiber (PMX-F) in patients with severe hyperdynamic shock treated with nor-epinephrine. Critical Care Medicine 24, A97.
75. Dong, Z., Qi, X., Xie, K. & Fidler, I. J. (1993). Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and iipopolysaccharide-nonresponsive murine macrophages. Journal of Immunology 151, 2717-24.
76. Rice, G. C., Brown, P. A., Nelson, R. J., Bianco, J. A., Singer, J. W. & Bursien, S. (1994). Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proceedings of the National Academy of Sciences of the United States of America 91, 3857-61.
77. French National Registry of HA-1A. (1994). The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Archives of Internal Medicine 154, 2484-91.
78. Proctor, R. A., Will, J. A., Burhop, K. E. & Raetz, C. R. H. (1986). Protection of mice against lethal endotoxemia by a lipid A precursor. Infection and Immunity 52, 905-7.